These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 15775701)

  • 21. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A; Hutagalung Y; Watanaveeradej V; Bock HL; Steinhoffmd M
    J Med Assoc Thai; 2007 Jul; 90(7):1330-6. PubMed ID: 17710973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
    Mornex F; Girard N; Scoazec JY; Bossard N; Ychou M; Smith D; Seitz JF; Valette PJ; Roy P; Rouanet P; Ducreux M; Partensky C
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1471-8. PubMed ID: 16793214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
    Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
    Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine Responses and Immunologic Characteristics of Pediatric Patients With DiGeorge Syndrome.
    Iroh Tam PY; McAllister SC
    Clin Pediatr (Phila); 2015 Nov; 54(13):1290-2. PubMed ID: 25573949
    [No Abstract]   [Full Text] [Related]  

  • 30. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.
    Gomez EV; Bishop JL; Jackson K; Muram TM; Phillips D
    BioDrugs; 2017 Dec; 31(6):545-554. PubMed ID: 29116597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer.
    Takhar AS; Gilliam AD; Watson SA; Henwood M; Rowlands BJ; Broome P; Beckingham IJ
    Eur J Surg Oncol; 2006 Mar; 32(2):197-200. PubMed ID: 16246519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy.
    Kawakubo K; Fernández-Del Castillo C; Liss AS
    J Gastroenterol; 2022 Nov; 57(11):827. PubMed ID: 36114896
    [No Abstract]   [Full Text] [Related]  

  • 33. Covid-19: 40% of patients with weakened immune system mount lower response to vaccines.
    Munro C
    BMJ; 2021 Aug; 374():n2098. PubMed ID: 34429324
    [No Abstract]   [Full Text] [Related]  

  • 34.
    Selvanesan BC; Chandra D; Quispe-Tintaya W; Jahangir A; Patel A; Meena K; Alves Da Silva RA; Friedman M; Gabor L; Khouri O; Libutti SK; Yuan Z; Li J; Siddiqui S; Beck A; Tesfa L; Koba W; Chuy J; McAuliffe JC; Jafari R; Entenberg D; Wang Y; Condeelis J; DesMarais V; Balachandran V; Zhang X; Lin K; Gravekamp C
    Sci Transl Med; 2022 Mar; 14(637):eabc1600. PubMed ID: 35320003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming Therapeutic Challenges for Pancreatic Ductal Adenocarcinoma with xCT Inhibitors.
    Vucetic M; Daher B; Cassim S; Parks S; Pouyssegur J
    Adv Exp Med Biol; 2021; 1301():7-24. PubMed ID: 34370285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.
    Asiry S; Kim G; Filippou PS; Sanchez LR; Entenberg D; Marks DK; Oktay MH; Karagiannis GS
    Front Immunol; 2021; 12():654877. PubMed ID: 33927723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database.
    Amin S; Baine M; Meza J; Alam M; Lin C
    Radiat Oncol; 2020 Jun; 15(1):139. PubMed ID: 32493354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.
    Aguilar LK; Shirley LA; Chung VM; Marsh CL; Walker J; Coyle W; Marx H; Bekaii-Saab T; Lesinski GB; Swanson B; Sanchez D; Manzanera AG; Aguilar-Cordova E; Bloomston M
    Cancer Immunol Immunother; 2015 Jun; 64(6):727-36. PubMed ID: 25795132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer.
    Goedegebuure P; Mitchem JB; Porembka MR; Tan MC; Belt BA; Wang-Gillam A; Gillanders WE; Hawkins WG; Linehan DC
    Curr Cancer Drug Targets; 2011 Jul; 11(6):734-51. PubMed ID: 21599634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
    Royal RE; Levy C; Turner K; Mathur A; Hughes M; Kammula US; Sherry RM; Topalian SL; Yang JC; Lowy I; Rosenberg SA
    J Immunother; 2010 Oct; 33(8):828-33. PubMed ID: 20842054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.